Interpreting the International Normalized Ratio (INR) in Individuals Receiving Argatroban and Warfarin

Summary

The effects of argatroban, a direct thrombin inhibitor, on the International Normalized Ratio (INR), activated partial thromboplastin time (aPTT) and functional factor X during warfarin co-administration were established to provide means to interpret INRs during argatroban/warfarin co-therapy. Twenty-four subjects receiving warfarin (7.5 mg, day 1; 3-6 mg/day, days 2-10) and argatroban (1-4 μg/kg/min over 5 h, days 1-11) were assessed daily for these coagulation parameters prior to argatroban infusion (warfarin “monotherapy”) and at its conclusion (“co-therapy”). Argatroban increased aPTTs dose-dependently. Co-therapy INR increased linearly with monotherapy INR, with slope sensitive to argatroban dose and thromboplastin used. Prediction errors for monotherapy INRs were ≤± 0.4 for argatroban 1-2 μg/kg/min but ≥± 1.0 for higher doses. Despite co-therapy INRs >7, no major bleeding occurred. Factor X remained ≥37% of normal. Therefore, the predictable effect of argatroban (≤ 2 mg/kg/min only) on INRs during warfarin co-therapy allows for reliable prediction of the level of oral anticoagulation.

Keywords

Argatroban - warfarin - direct thrombin inhibitors - International Normalized Ratio

• References

• 1 Lewis BE, Wallis DE, Matthai W. Argatroban provides effective and safe anticoagulation in patients with heparin-induced thrombocytopenia: A prospective, historical controlled study [abstract]. J Am Coll Cardiol 2000; 35 (Suppl A) 266A.
• 2 Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, Mueller-Velten HG, Potzsch B. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999; 73-80.
• 3 Fareed J, Callas D, Hoppensteadt DA, Lewis BE, Bick RL, Walenga JM. Antithrombin agents as anticoagulants and antithrombotics: Implications in drug development. Semin Hematol 1999; 36 (Suppl. 01) 42-56.
• 4 Zoldhelyi P, Webster M, Fuster V, Grill DE, Gaspar D, Edwards SJ, Cabot CF, Chesebro JH. Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 1993; 88: 2015-22.
• 5 Cannon CP, Maraganore JM, Loscalzo J, McAllister A, Eddings K, George D, Selwyn AP, Adelman B, Fox I, Braunwald E, Ganz P. Anticoagulant effects of Hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol 1993; 71: 778-82.
• 6 Hauptmann J, Kaiser B, Nowak G, Sturzebecker J, Markwardt F. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Thromb Haemost 1990; 63: 220-3.
• 7 Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J. Anticoagulant activity of Hirulog™, a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69: 157-63.
• 8 Bichler J, Fichtl B, Siebeck M, Fritz H. Pharmacokinetics and pharmaco-dynamics of hirudin in man after single subcutaneous and intravenous bolus administration. Arzneim-Forsch/Drug Res 1988; 38: 704-10.
• 9 Rao AK, Sun L, Chesebro JH, Fuster V, Harrington RA, Schwartz D, Gallo P, Matos D, Topol EJ. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina: a multicenter trial. Circulation 1996; 94: 2389-95.
• 10 Nagasawa H, Fukutake K, Hada M, Takahashi E, Matubara Y, Samori T, Ikematsu S, Kitahara T, Ukita M, Fujimaki M, Fukutake K. Phase one study of synthetic antithrombin agent (MD-805) single and multiple administration studies. Jpn J. Clin Pharmacol Therap 1981; 12: 359-75.
• 11 Callas D, Fareed J. Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Thromb Haemost 1995; 74: 473-81.
• 12 Nichols WL, Bowie EJ. Standardization of the prothrombin time for monitoring orally administered anticoagulant therapy with use of the international normalized ratio system. Mayo Clin Proc 1993; 68: 897-8.
• 13 Okamoto S, Hijikata-Okunomiya A. Synthetic selective inhibitors of thrombin. Methods Enzymol 1993; 222: 328-40.
• 14 Hursting MJ, Becker JC, Joffrion JL, Knappenberger GD, Schwarz RP. Monitoring warfarin during concurrent argatroban therapy in healthy volunteers: Use of the International Normalized Ratio versus factor X by amid-olytic assay [abstract]. Blood 1997; 90 (Suppl. 01) 116b.
• 15 Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318-329.
• 16 Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP. The International Normalized Ratio during concurrent warfarin and argatroban anticoagulation: Differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem 1999; 45: 409-12.
• 17 Weiss P, Soff GA, Halkin H, Seligsohn U. Decline of proteins C and S and factors II, VII, IX and X during the initiation of warfarin therapy. Thromb Res 1987; 45: 783-90.
• 18 Hoppensteadt D, Kahn S, Fareed J. Factor X values as a means to assess the extent of oral anticoagulation in patients receiving antithrombin drugs. Clin Chem 1997; 43: 1786-8.
• 19 Seber, GAF.. Linear Regression. New York, NY: John Wiley & Sons; 1977: 187-9.
• 20 Hirsh J. Mechanism of action and monitoring of anticoagulants. Sem Thromb Hemost 1986; 12: 1-11.
• 21 Ebert R. PTs, PRs, ISIs, and INRs: A primer on prothrombin time reporting. Part II: Limitations of INR reporting. Clin Hemost Rev 1993; 7: 1-9.
• 22 American Society of Health-System Pharmacists.. ASHP therapeutic position statement on the use of the International Normalized Ratio system to monitor oral anticoagulant therapy. Am J Health-Syst Pharm 1995; 52: 529-31.
• 23 Zivelin A, Rao LVM, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest 1993; 92: 2131-40.
• 24 Antman EM. Hirudin in acute myocardial infarction: thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996; 94: 911-21.